Secondary outcomes
ICU-acquired weakness, ARDS
SECONDARY, ARDS, VENTILATOR-ASSOCIATED PNEUMONIA
Secondary outcomes were not significantly different between groups. Following treatment with prostacyclin, the mortality rate did not improve when analyzing all patients with ARDS (Fig. Overall survival in the total study cohort and COVID-19 positive patientsWhen analyzing the subset of patients with COVID-19, we found that the secondary outcomes were not significantly different between groups. In this subgroup of patients, treatment with prostacyclin did not improve secondary outcomes. The SOFA score of patients with COVID-19 was not improved on Days 7, 14 and 28. The duration of mechanical ventilation and ICU length of stay did not differ between groups of patients with COVID-19. The incidence of ventilator-associated pneumonia, discharge location and ICU-acquired weakness also did not change in patients with COVID-19 following treatment with prostacyclin.